Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

UBS Maintains Buy on Applied Therapeutics, Raises Price Target to $12

Author: Benzinga Newsdesk | March 06, 2024 01:38pm
UBS analyst Esther Rajavelu maintains Applied Therapeutics (NASDAQ:APLT) with a Buy and raises the price target from $4 to $12.

Posted In: APLT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist